Rhumbline Advisers Cytom X Therapeutics, Inc. Transaction History

Rhumbline Advisers

  • $103 Billion
  • Q1 2024

A detailed history of Rhumbline Advisers transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 1,291 shares of CTMX stock, worth $1,678. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,291
Previous 1,291 -0.0%
Holding current value
$1,678
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 08, 2023
BUY
$1.41 - $1.92 $1,820 - $2,478
1,291 New
1,291 $2,000
Q2 2022

Aug 11, 2022
SELL
$1.53 - $2.89 $103,085 - $194,716
-67,376 Closed
0 $0
Q1 2022

May 12, 2022
BUY
$2.67 - $4.68 $1,142 - $2,003
428 Added 0.64%
67,376 $180,000
Q4 2021

Feb 10, 2022
SELL
$3.87 - $7.39 $3,811 - $7,279
-985 Reduced 1.45%
66,948 $290,000
Q3 2021

Nov 12, 2021
BUY
$4.32 - $6.43 $16,230 - $24,157
3,757 Added 5.85%
67,933 $346,000
Q2 2021

Aug 05, 2021
BUY
$6.33 - $9.91 $20,192 - $31,612
3,190 Added 5.23%
64,176 $406,000
Q1 2021

May 06, 2021
BUY
$6.6 - $9.0 $12,177 - $16,605
1,845 Added 3.12%
60,986 $471,000
Q4 2020

Feb 10, 2021
BUY
$6.47 - $7.9 $21,415 - $26,149
3,310 Added 5.93%
59,141 $387,000
Q3 2020

Nov 12, 2020
SELL
$6.55 - $8.83 $51,024 - $68,785
-7,790 Reduced 12.24%
55,831 $371,000
Q2 2020

Aug 13, 2020
BUY
$7.4 - $14.64 $21,874 - $43,275
2,956 Added 4.87%
63,621 $530,000
Q1 2020

May 06, 2020
SELL
$3.61 - $8.6 $6,100 - $14,534
-1,690 Reduced 2.71%
60,665 $465,000
Q4 2019

Feb 05, 2020
BUY
$5.17 - $8.91 $5,929 - $10,219
1,147 Added 1.87%
62,355 $518,000
Q3 2019

Oct 23, 2019
BUY
$7.38 - $12.25 $6,796 - $11,282
921 Added 1.53%
61,208 $452,000
Q2 2019

Aug 14, 2019
BUY
$9.35 - $11.41 $23,375 - $28,525
2,500 Added 4.33%
60,287 $676,000
Q1 2019

May 01, 2019
SELL
$9.5 - $19.16 $12,882 - $25,980
-1,356 Reduced 2.29%
57,787 $621,000
Q4 2018

Jan 31, 2019
BUY
$12.69 - $18.61 $271,591 - $398,291
21,402 Added 56.71%
59,143 $893,000
Q3 2018

Nov 07, 2018
BUY
$18.04 - $26.41 $12,429 - $18,196
689 Added 1.86%
37,741 $698,000
Q2 2018

Aug 06, 2018
BUY
$21.38 - $29.68 $173,178 - $240,408
8,100 Added 27.98%
37,052 $847,000
Q1 2018

May 02, 2018
BUY
$21.76 - $34.22 $4,352 - $6,844
200 Added 0.7%
28,952 $824,000
Q4 2017

Feb 09, 2018
SELL
$19.0 - $23.09 $80,655 - $98,017
-4,245 Reduced 12.86%
28,752 $607,000
Q3 2017

Nov 06, 2017
BUY
$13.53 - $18.17 $446,449 - $599,555
32,997
32,997 $600,000

Others Institutions Holding CTMX

# of Institutions
89
Shares Held
43.9M
Call Options Held
105K
Put Options Held
4.5K
View Full List

About CytomX Therapeutics, Inc.

CTMX Quotes by TradingView
  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $85.7M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email